CO2024004628A2 - Composiciones y métodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinación de thc y melatonina - Google Patents

Composiciones y métodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinación de thc y melatonina

Info

Publication number
CO2024004628A2
CO2024004628A2 CONC2024/0004628A CO2024004628A CO2024004628A2 CO 2024004628 A2 CO2024004628 A2 CO 2024004628A2 CO 2024004628 A CO2024004628 A CO 2024004628A CO 2024004628 A2 CO2024004628 A2 CO 2024004628A2
Authority
CO
Colombia
Prior art keywords
compositions
thc
melatonin
compounds
methods
Prior art date
Application number
CONC2024/0004628A
Other languages
English (en)
Spanish (es)
Inventor
Ramachandra Mukunda
Jagadeesh S Rao
Original Assignee
Igc Pharma Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igc Pharma Ip Llc filed Critical Igc Pharma Ip Llc
Publication of CO2024004628A2 publication Critical patent/CO2024004628A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2024/0004628A 2021-09-17 2024-04-12 Composiciones y métodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinación de thc y melatonina CO2024004628A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245799P 2021-09-17 2021-09-17
PCT/US2022/076579 WO2023044433A1 (en) 2021-09-17 2022-09-16 Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin

Publications (1)

Publication Number Publication Date
CO2024004628A2 true CO2024004628A2 (es) 2024-05-10

Family

ID=83688895

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0004628A CO2024004628A2 (es) 2021-09-17 2024-04-12 Composiciones y métodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinación de thc y melatonina

Country Status (8)

Country Link
US (1) US20250275935A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401717A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024535871A (cg-RX-API-DMAC7.html)
CA (1) CA3232209A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000782A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024004628A2 (cg-RX-API-DMAC7.html)
PE (1) PE20241236A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023044433A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
CN121040357A (zh) * 2024-06-04 2025-12-02 河北农业大学 一种增加黄水仙生物碱加兰他敏的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR44305E (fr) 1933-12-09 1934-12-24 Meaf Mach En Apparaten Fab Nv Circuits de voie à rails sans potentiel ou portés au même potentiel
US11065225B1 (en) 2015-07-30 2021-07-20 University Of South Florida Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease
US10525093B2 (en) * 2016-11-14 2020-01-07 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
US20200246404A1 (en) * 2017-02-15 2020-08-06 Molecular Infusions, Llc Formulations
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
MX2020010284A (es) 2018-03-30 2021-02-18 India Globalization Capital Inc Método y composición para el tratamiento de los trastornos del snc.
EP4025199A4 (en) * 2019-07-12 2023-08-02 University of South Florida Compositions and methods for treating alzheimers disease

Also Published As

Publication number Publication date
CA3232209A1 (en) 2023-03-23
EP4401717A1 (en) 2024-07-24
JP2024535871A (ja) 2024-10-02
PE20241236A1 (es) 2024-06-19
US20250275935A1 (en) 2025-09-04
CL2024000782A1 (es) 2024-09-23
WO2023044433A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
Wang et al. Silibinin prevents autophagic cell death upon oxidative stress in cortical neurons and cerebral ischemia-reperfusion injury
US12465589B2 (en) Method and composition for treating CNS disorders
CL2024000782A1 (es) Composiciones y métodos para tratar pacientes con demencia por enfermedad de alzheimer
MX2021009646A (es) Uso de cannabinoides en el tratamiento de epilepsia.
EP4640275A3 (en) USE OF CANNABIDIOL IN THE TREATMENT OF ANGELMAN SYNDROME ANXIETY
ES3064032T3 (en) Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies
Jiang et al. Inhibition of the integrated stress response reverses oxidative stress damage-induced postoperative cognitive dysfunction
MX2020005719A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2017011280A (es) Terapia neuro-afectiva regional topica con cannabinoides.
CA2956919C (en) Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids
Tao et al. Advances in autophagy modulation of natural products in cervical cancer
Zhang et al. Hypericin-photodynamic therapy induces human umbilical vein endothelial cell apoptosis
CR20220250A (es) Métodos para el tratamiento de trastornos depresivos
BR112022021640A2 (pt) Usos e formulações de canabinoides
Tang et al. Eriodictyol inhibits the growth of CNE1 human nasopharyngeal cancer growth by targeting MEK/ERK signalling pathway, inducing cellular autophagy and inhibition of cell migration and invasion
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
Chauhan et al. Ginkgo biloba administered singly and combined with antioxidants in tinnitus patients
Joseph et al. Effects of aerobic exercise and dietary flavonoids on cognition: a systematic review and meta-analysis
Kumar The promise of nutrient-derived bioactive compounds and dietary components to ameliorate symptoms of chemotherapy-related cognitive impairment in breast cancer survivors
WO2021127749A1 (en) Compositions comprising terpenes and their use in the treatment or alleviation of pain or anxiety
Negi et al. Neurovascular Coupling Dysfunction: Natural Products as a Remedy to Manage Neurodegenerative Disorders
Habib et al. Isoflavones and alzheimer’s disease: The effects of soy in diet
Del-Bel et al. Cannabidiol in neurology and psychiatry
Katiyar et al. Nutraceuticals and phytotherapeutics for holistic management of amyotrophic lateral sclerosis
Stolf et al. Pharmacological study of a cannabinoid-containing eyedrop formulation in dogs and mice